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Survival after massive intentional overdose of paraquat
Umesh G Lalloo, Anish Ambaram
To the Editor: Survival following oral ingestion of a large 
volume of paraquat is rare. Our patient ingested approximately 
200 ml of paraquat and survived, following aggressive 
intervention. He developed oral pharyngeal ulceration, acute 
lung injury, haematemesis, haemoptysis and renal failure. He 
was treated with a combination of pulse methylprednisolone, 
vitamins C and E, and N-acetylcysteine. We propose a 
rationale for high-dose antioxidant treatment in addition to 
corticosteroids and intensive care. 
Case report
A 20-year-old man was referred to our critical care unit 16 
hours after the intentional ingestion of several mouthfuls 
of paraquat (1,1’-dimethyl-4,4’-bipyridinium dichloride 
(Gramoxone; Syngenta, Namibia)), taken directly from a 5-litre 
container. He vomited approximately a cupful of blood several 
hours after the ingestion, and vomited greenish fluid several 
times thereafter. He was given milk by his family, taken to a 
local hospital and transferred to our care. 
On admission the patient was lucid and had normal 
levels of arterial blood gases. His blood pressure was 130/70 
mmHg, his pulse rate 80 beats/min and his respiratory rate 
20/min; urea, creatinine and electrolyte levels were normal; 
the white cell count was 1.6×109/l; examination of the urine 
showed 2+ blood and protein; and the chest radiograph was 
normal. Serum creatinine kinase peaked at 532 U/l on day 3 
(MB fraction 10%). Liver function was normal. His posterior 
pharynx was erythematous. Immediate management comprised 
50 g activated charcoal 4-hourly per nasogastric tube until his 
stools were black (day 5), and intravenous 0.9% saline 80 ml/
hour. 
Aggressive treatment was introduced in view of the grim 
prognosis. He was given intravenous methylprednisone 1 g stat 
and daily for 3 days, vitamin C 100 mg 4-hourly for 14 days, 
and an infusion of N-acetylcysteine at 150 mg/kg for 1 hour, 50 
mg/kg over the next 4 hours, then 100 mg/kg daily for 4 days. 
Vitamin E, 50 mg daily, was commenced on day 5 for 12 days, 
when oral medication was possible after cessation of activated 
charcoal treatment.
Renal failure developed on day 2; haemodialysis was 
commenced on day 5 and continued up to day 15. The patient 
became tachypnoeic and hypoxic on day 3 and had bilateral 
chest crackles on auscultation. A chest radiograph showed 
bilateral mild infiltrates and he was given supplemental 40% 
oxygen via a facemask. Renal function returned to normal. His 
hospital stay was complicated by episodes of haemoptysis, 
nosocomial pneumonia on day 14, and right axillary and 
subclavian vein thrombosis on day 20 attributed to a central 
venous catheter. He was discharged on day 15 and continued 
on oral anticoagulant treatment. 
Discussion
Survival following a massive overdose of paraquat is extremely 
rare. We used a combination of corticosteroid and antioxidant 
treatment on the hypothesis that mortality is due to respiratory 
failure and that the toxicity is primarily oxidant mediated. We 
were unable to measure paraquat levels as the recommended 
urine dithionite test for paraquat was not available at our 
institution. The volume of paraquat solution ingested by our 
patient was estimated to be about 200 ml (several mouthfuls). 
The lethal dose according to the manufacturer is 3 - 5 mg/kg 
(10 - 15 ml of the 20% solution). The history and clinical course 
of the patient conformed to massive ingestion of paraquat 
attenuated by the combination of intensive care and high-dose 
antioxidant and corticosteroid treatment.
Accidental paraquat poisoning is common globally because 
of its widespread use as a herbicide in agriculture. Systemic 
absorption usually occurs via exposed skin during spraying 
of paraquat. High-dose exposure occurs with oral ingestion, 
usually as a suicide attempt. Based on the low lethal dose, 
oral ingestion is almost invariably fatal because of progressive 
diffuse alveolar damage and rapidly progressive acute 
respiratory distress syndrome (ARDS).
Approximately 20% of ingested paraquat is absorbed.1 An 
empty stomach and pre-existing gastrointestinal ulceration 
increase absorption. Toxicity is manifested by oedema and 
ulceration of the mouth, pharynx, oesophagus, stomach and 
intestines. Paraquat has multiple sites of toxicity. It is rapidly 
metabolised to peroxynitrite, the effects of which depend on 
the site of action as well as the levels of antioxidant achieved 
in vivo and duration of exposure.2 It is a strong oxidant and 
nitrating intermediate that reacts with proteins, lipids and 
DNA via direct or radical mediated mechanisms. This results in 
altered enzyme activities and signalling pathways2 and a major 
disruption of nicotinamide adenosine dinucleotide phosphate 
(NADPH)-dependent cellular processes.3
The lungs are the primary target organ of paraquat 
toxicity and account for the mortality in most instances.4 
Pulmonary damage is a result of oxidative stress to the 
alveolar epithelium which actively takes up paraquat (and 
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its metabolites).  Acute pulmonary oedema and early lung 
damage may occur within a few hours of acute severe 
exposure. Haemorrhage, proteinaceous oedema fluid, and 
leucocyte infiltration into alveolar spaces may occur, followed 
by rapid proliferation of fibroblasts.5 Delayed pulmonary 
damage resulting in pulmonary fibrosis occurs between 7 and 
14 days after ingestion. Our patient appears to have had an 
attenuated delayed pulmonary reaction, probably as a result 
of the therapeutic intervention. He had several episodes of 
haemoptysis and mild pulmonary infiltrates that did not 
progress to florid respiratory failure and ARDS. Reversal of 
pulmonary fibrosis several months after ingestion of paraquat 
has been reported.5 Circulatory failure has also been reported 
in patients who ingested a large volume of concentrated (20%) 
solution. Shock and death within 48 hours of ingestion has 
been reported.4
As toxicity progresses, centrizonal hepatocellular injury may 
develop, manifesting as hepatocellular enzyme elevation and 
hyperbilirubinaemia. Renal toxicity may play an important role 
in determining survival because normal tubular cells actively 
secrete paraquat into the urine, thereby decreasing its toxicity. 
Haemodialysis was only introduced in our patient when renal 
failure manifested; he recovered renal function within 14 days.
Other sites of injury include skeletal and cardiac muscle, 
which manifests with elevated muscle enzymes. Our patient 
had a transient elevation in his muscle enzymes which peaked 
on day 3. We submit that muscle injury might have been 
attenuated by treatment.
The results of management of paraquat poisoning have 
been disappointing. These have included adsorbents, 
pharmacological approaches6 and radiotherapy,7 haemodialysis 
and haemoperfusion.8 Our patient’s therapeutic regimen 
maximised antioxidant effects with available agents, including 
N-acetylcysteine based on the regimen for paracetamol 
overdose, vitamin C, and vitamin E.  N-acetylcysteine  
significantly improves mortality in paraquat-intoxicated 
rats,9 and its use in lung disease was extrapolated from its 
application in idiopathic pulmonary fibrosis.10 High-dose 
corticosteroid treatment was determined from the study by 
Chen et al.11 Methylprednisolone improved histology but not 
oxygenation in a rat model of paraquat-induced lung injury.12 
Other studies, however, have not shown improvement in 
histology and surfactant in rats that were pre-treated with 
methylprednisolone.13 Repeated pulses of methylprednisolone 
and cyclophosphamide with continuous dexamethasone 
therapy showed a 54% improvement in survival (p=0.027) in 
patients with a 50 - 90% predictive mortality.14,15
Intravenous cyclophosphamide has been recommended,16 
but we elected not to use it in our patient as it may be toxic 
and its therapeutic rationale is not clear. Decreased vitamin 
C and E levels have been demonstrated in rats after paraquat 
administration,17  and vitamin E has neuroprotective effects on 
rat striatal neurons after oxidative stress caused by paraquat, 
providing further rationale for the use of these vitamins.18 
These antioxidants might have contributed to the treatment of 
oxidant stress associated with paraquat toxicity.
There have been no reports on the use of N-acetylcysteine 
together with methylprednisolone and other antioxidants such 
as vitamins C and E. We propose that our patient survived 
a potentially lethal dose of paraquat because of the massive 
doses of antioxidants administered. Fig. 1 outlines the rationale 
for our therapeutic intervention and the proposed mechanism 
of toxicity. Human studies are impossible, and prevention of 
paraquat toxicity is important. We recommend that large doses 
of antioxidants and corticosteroids are given empirically in the 
event of poisoning, which may also be a potential therapeutic 
strategy for acute lung injury of other causes.
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Fig. 1. Schematic representation of the metabolism, toxicity and proposed 
sites of action of drugs (red arrows) used in the management of paraquat 
toxicity.
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Coronary spasm and thrombosis in a bodybuilder using a 
nutritional supplement containing synephrine, octopamine, 
tyramine and caffeine
J P Smedema, G J Müller
To the Editor: A young, previously healthy bodybuilder 
suffered an acute myocardial infarction in the absence 
of known cardiovascular risk factors or demonstrable 
atherosclerotic plaque. The infarction probably resulted from 
coronary spasm, platelet activation and in situ thrombosis 
triggered by the chronic consumption of a ‘nutritional 
supplement’ which contains synephrine, octopamine, tyramine 
and caffeine.
The 39-year-old bodybuilder presented after developing 
new-onset angina pectoris with vegetative symptoms 
during a bodybuilding competition. He had no previous 
medical history or cardiovascular risk factors, and denied 
ever using androgenic anabolic steroids. He had been 
involved in competitive bodybuilding for 7 years. He had 
been taking for several years a ‘nutritional supplement’ 
that contains synephrine (oxedrine), octopamine, tyramine 
(sympathomimetic amines) and caffeine. The preparation 
also contains several ‘nutrients’, of which the herb St John’s 
wort has significant pharmacological actions on the nervous 
system.1 In the 3 months preceding the competition concerned, 
he had taken a daily dose equivalent to 40 mg synephrine, 
400 mg caffeine, and an unspecified amount of tyramine 
and octopamine. Synephrine is more potent than the other 
sympathomimetic amines. Its action is similar to that of 
phenylephrine, an alpha-adrenergic agonist,2 and it has been 
used for treating hypotension in doses of about 100 mg 3 times 
a day. Octopamine has about one-hundredth the potency of 
noradrenaline. 
The patient had restricted his fluid intake and increased 
his carbohydrate intake during the 36 hours before the 
competition. Physical examination was normal. The 
electrocardiogram showed a wide right bundle-branch block 
that resolved after several hours, and 1 mm ST-segment 
elevation in leads II, III, aVF, and V4-6. There was evidence 
of renal impairment, with creatinine at 171 μmol/l and 
urea at 11 mmol/l, and creatine kinase (CK) levels of 8 500 
IU/l. The troponin T level was normal on admission, but 
rose to 0.53 ng/ml after 6 hours, and 1.9 ng/ml after 24 
hours. Echocardiography demonstrated a dyskinetic basal 
interventricular septum, with mild biventricular hypertrophy. 
Oral aspirin, clopidogrel and bisoprolol and intravenous 
nitroglycerine, enoxiparine and eptifibatide were initiated, 
and he was hydrated with intravenous 0.9% saline. Coronary 
angiography showed a thrombus in the proximal left anterior 
descending artery, with diffuse spasm in the mid- and distal 
segments (Fig. 1), which resolved after the administration 
of intracoronary nitroglycerine. A 4.5 mm bare metal stent 
covering the lesion was successfully positioned. His low-
density lipoprotein, high-density lipoprotein and triglyceride 
levels were respectively 2.1, 0.31 and 1 mmol/l, the fasting 
homocysteine level was normal, and anti-phospholipid 
antibodies were absent. He was discharged fully recovered and 
remains symptom-free 6 months later.
Discussion
The acute myocardial infarction in this young, previously 
healthy bodybuilder in the absence of known cardiovascular 
risk factors or demonstrable atherosclerotic plaque was 
probably caused by coronary spasm, platelet activation and in 
situ thrombosis.
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The USA’s Food and Drug Administration (FDA) banned 
the sale of products containing ephedrine alkaloids in 2004 
because of associated cardiovascular toxicity.3 Synephrine and 
octopamine are structurally similar to norepinephrine, and 
have been associated with acute myocardial infarction and 
ischaemic colitis. 4-7 Both are trace endogenous bioamines, 
agonists of the α1, α2, β1 and β3 adrenoreceptors, are found 
in human plasma, platelets, sympathic nerves and adrenal 
tissue, and are present in Citrus aurantium (Seville orange, 
bitter orange), an ingredient in dietary supplements marketed 
for weight loss.8-10 In animal studies, synephrine increased 
cardiac output and caused vasoconstriction and ventricular 
arrhythmias.11,12 Bitter orange has been identified as a cause 
of resistant hypertension, syncope, myocardial infarction, 
tachycardia and ventricular fibrillation, and exacerbated 
coronary spasm in tobacco smokers.5 Prolonged administration, 
or the combined consumption, of synephrine with octopamine 
and caffeine may result in haemodynamic effects.13-16 A single 
dose of bitter orange extract containing the equivalent of  
50 mg synephrine significantly increased the systolic and 
diastolic blood pressures, as well as the heart rate, of healthy 
young adults for up to 5 hours.17
The risk of adverse cardiovascular events may be higher in 
persons with pre-existing underlying cardiovascular disease. 
Caffeine enhances the cardiovascular and central nervous 
system effects of adrenergic amines though augmentation 
of catecholamine release.18-20 The enhanced sympathetic 
activity increases platelet reactivity. Although an underlying 
atheromatous plaque has not been excluded with absolute 
certainty in our patient, it seems very likely that use of a 
nutritional supplement containing synephrine, octopamine, 
tyramine and caffeine, combined with intravascular 
dehydration and impaired renal function, triggered coronary 
spasm and thrombosis of a major proximal coronary artery. 
Constituents of St John’s wort are inhibitors of serotonin, 
noradrenaline and dopamine uptake in the synaptic cleft,1 
which may potentiate the effects of alpha-adrenergic stimulants 
and thereby enhance their vasoconstrictor activities.
The safety of over-the-counter supplements containing 
synephrine has been called into question.4-8 Consumers 
consider dietary supplements to be safe, but these are 
currently not subjected to scientific scrutiny, and some contain 
potentially harmful ingredients. The use of supplements 
containing the combination of synephrine, octopamine, 
tyramine and caffeine may constitute a risk of cardiovascular 
toxicity. There is a need for centralised monitoring of clinical 
adverse events in consumers using nutritional supplements.
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
Fig. 1. Diagnostic coronary angiogram (postero-anterior view), demon-
strating thrombus in the proximal left anterior descending coronary artery 
(arrow), and diffuse spasm of the mid and distal segments of the vessel 
(arrowheads).
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